Navigation Links
Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
Date:12/9/2008

progression has not yet been established for this study.

According to Dr. Vij, "Single-agent carfilzomib has shown impressive and durable activity, notably among patients who have failed transplantation and have not yet received treatment with a proteasome inhibitor. The emerging safety profile makes this an attractive option in patients who have pre-existing neuropathy. Continued evaluation of carfilzomib in less heavily pre-treated patients is warranted given these promising findings."

Carfilzomib was generally well tolerated among relapsed patients and toxicities were manageable. The most common adverse events were fatigue, anemia and neutropenia. Two cases of tumor lysis syndrome were observed among bortezomib-naive patients, and with additional monitoring and management guidelines no further events have been reported. No treatment-emergent Grade 3 or 4 peripheral neuropathy was reported in this study.

Dr. Vij presented these interim data from a study of relapsed patients in a presentation titled Initial Results of PX-171-004, an Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed Multiple Myeloma (MM) (Abstract #865).

"We are encouraged by the data that show that carfilzomib is active and has been successful in providing durable responses in patients who have relapsed or who do not respond to currently available treatment options," said Lori A. Kunkel, M.D., Proteolix's Chief Medical Officer. "We believe carfilzomib may have broad application in the treatment of hematologic malignancies and solid tumors."

Supporting Preclinical Data

In addition to the two oral presentations of Phase 2 clinical data, Proteolix scientists presented results of preclinical studies that further characterize the mechanism and safety profile of carfilzomib. These data were presented on Sunday, December 7 in two poster presentations: Non-Proteasom
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... TX (PRWEB) August 29, 2014 ... ISO 13485:2003 certified, GAMP® 5 compliant imaging core ... an international Phase II clinical trial to assess ... , Throughout this trial, Intrinsic Imaging will provide ... limited to, protocol and charter development, site qualification, ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
(Date:8/28/2014)... , Aug. 28, 2014   SunTrust Robinson ... three industry veterans to its equity research team ... "Our ongoing expansion in equity research demonstrates our ... unique insights to enhance their investment decision making," ... at STRH.  "We continue to make significant investments ...
(Date:8/28/2014)... Vt. (PRWEB) August 28, 2014 ... testing around the world is available from Strategic ... diagnostics companies. “ Industrial Microbiology Market Review, Fourth ... Industrial Market ” (IMMR—4) tracks and compares microbiology ... in North America, Europe and Asia, and forecasts ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3
... (TB) Expected to Highlight Broad On-Demand CE IVD Test ... (Nasdaq: CPHD ) today announced speaker and ... the Era of Rapid Diagnostics ," which the company ... Microbiology and Infectious Diseases (ECCMID), taking place in Finland ...
... Management Product Line , ... San Jose, CA (PRWEB) ... of laboratory supplies and instrumentation to academic, biotech and pharmaceutical research ... and sample management solutions. E&K is now serving as distributor ...
... vaccine delivered through skin patches containing microneedles has ... mice as intramuscular, hypodermic flu immunization. A team ... Institute of Technology believes the new microneedle skin ... overall seasonal vaccination coverage in people because of ...
Cached Biology Technology:Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 3Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 4Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 5E&K Scientific Announces Partnership with Sciformatix 2Flu vaccine given in microneedle skin patches proves effective in mice 2Flu vaccine given in microneedle skin patches proves effective in mice 3
(Date:8/28/2014)... German . Cars, ... help of sophisticated assembly lines. Mobile assembly carriers, on to ... these assembly lines. In the case of a car body, ... in a precise spatial and chronological sequence, resulting in a ... creation of such an assembly line at molecular level has ...
(Date:8/28/2014)... person to alert the world to Global Warming, has ... and stored underground. He says that Carbon Capture, combined ... way to avoid global warming getting out of control ... New York) made the call during his presentation to ... scientists are meeting to discuss Carbon Capture and Storage. ...
(Date:8/28/2014)... action is needed to ensure safeguards are in place ... PLOS ONE , researchers from Monash University, Stellenbosch ... combining results from different studies - to look at ... to determine whether they actually protect biodiversity. , ... an area from human exploitation made common sense, however, ...
Breaking Biology News(10 mins):Nanoscale assembly line 2Nanoscale assembly line 3Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground 2Protected areas proven to protect biodiversity 2
... life-threatening infection in the body, a virus such as HIV ... cell's outer membrane. Once inside the cell, the invading microbe's ... factory to produce more copies of the virus, which then ... Scientists had assumed that once a virus begins fusing with ...
... Laboratory (LLNL) and the Linnaeus Centre for Bioinformatics (LCB) ... bioinformatics technique for systematically analyzing key regions in DNA ... headed by Krzysztof Fidelis in the United States and ... regulatory mechanisms that tell genes when to switch on ...
... have discovered a new phenomenon in which one bacterial cell ... bacteria that stop growing may go into a dormant state, ... chronic diseases, such as urinary tract infections. , The discovery ... David Low, professor of biology at the University of California, ...
Cached Biology News:Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 3New bioinformatics technique for systematically analyzing key regions in DNA that help control gene activity 2One bacteria stops another on contact 2
Ready-to-use solution....
Applications: ISH...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
Biology Products: